Dose Escalation of Bivatuzumab Mertansine in Female Patients With CD44v6 Positive Recurrent or Metastatic Breast Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Breast Neoplasms
Interventions: DRUG: bivatuzumab mertansine
Sponsor: Boehringer Ingelheim